Search results for "From ACP Internist Weekly"
Almost 4 in 10 with type 1 diabetes were diagnosed in adulthood
Peak diagnosis age was approximately 15 years, and the median age of diagnosis was 24 years, but 37% of adults with type 1 diabetes reported having been diagnosed after age 30 years in a recent study.
https://diabetes.acponline.org/archives/2023/10/13/9.htm
13 Oct 2023
Rosuvastatin, atorvastatin compared on effectiveness, safety in industry-funded trial
Analysis of a randomized trial in South Korea found that patients randomized to rosuvastatin developed type 2 diabetes requiring medication at a rate of 7.2%, compared to 5.3% among those given atorvastatin.
https://diabetes.acponline.org/archives/2023/11/10/8.htm
10 Nov 2023
‘Night owls' more likely to have unhealthy lifestyles, higher diabetes risk
In a retrospective cohort study, people with an evening chronotype were more likely to smoke, sleep poorly, and be physically inactive and had a 72% higher risk for diabetes than those with a morning chronotype.
https://diabetes.acponline.org/archives/2023/10/13/11.htm
13 Oct 2023
Higher aspirin dose no more effective for CV prevention in high-risk patients with diabetes
A subgroup analysis of a randomized trial found that patients with diabetes and atherosclerotic cardiovascular (CV) disease had similar outcomes whether they took 81 mg or 325 mg of aspirin daily.
https://diabetes.acponline.org/archives/2023/10/13/10.htm
13 Oct 2023
SGLT-2 inhibitors reduced gout flares in patients with diabetes, gout
New users of sodium-glucose cotransporter-2 (SGLT-2) inhibitors had about half the risk of an ED visit or hospitalization for a gout flare as matched patients taking dipeptidyl peptidase-4 inhibitors, a cohort analysis found.
https://diabetes.acponline.org/archives/2023/08/11/7.htm
11 Aug 2023
Nonsugar sweeteners should not be used for weight loss, WHO guideline states
The World Health Organization (WHO) cited a lack of evidence suggesting that short-term use of nonsugar sweeteners affected body weight or other measures of adiposity, as well as possible long-term undesirable effects on noncommunicable diseases and death.
https://diabetes.acponline.org/archives/2023/06/09/7.htm
9 Jun 2023
Kidney failure, CV events lower with canagliflozin than placebo, industry study finds
The trial was stopped early after an interim safety analysis found significantly better renal and cardiovascular outcomes among type 2 diabetes patients randomized to canagliflozin than those assigned to placebo.
https://diabetes.acponline.org/archives/2019/05/10/10.htm
10 May 2019
SGLT2 inhibitors associated with rare, life-threatening necrotizing genital infections
In the past six years, nearly three times as many cases of Fournier gangrene were reported in patients taking sodium-glucose cotransporter-2 (SGLT2) inhibitors as in the past 35 years in patients taking other antiglycemic agents.
https://diabetes.acponline.org/archives/2019/05/10/11.htm
10 May 2019
Large review compares benefits, harms of drugs to treat type 2 diabetes
High-certainty evidence indicated that sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists reduce all-cause death, while finerenone probably also reduced mortality based on moderate-certainty evidence.
https://diabetes.acponline.org/archives/2023/05/12/6.htm
12 May 2023
Some newer diabetes drugs may help decrease risk of COPD exacerbation
A cohort study in the United Kingdom found that chronic obstructive pulmonary disease (COPD) exacerbations were less common in patients with type 2 diabetes and COPD taking glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors versus sulfonylureas.
https://diabetes.acponline.org/archives/2022/11/11/6.htm
11 Nov 2022